Live Analyst Rating Changes 4914 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Tao Qiu
MACQ
Tao Qiu
Macquarie
Wall Street Analyst
★★★☆☆
#1167
on 13Foresight · ranked by our own returns
69%
Success Rate
+14.9%
Average Return
11 of 16 calls profitable · -6.7% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 69% of Tao Qiu's ratings turned a profit when each position was held for 1 year — averaging +14.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

1 Buy 0 Hold 0 Sell
Tao's Stock Coverage 15 ratings · 2026-07-04
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
HCSG
Healthcare Services
 Jul 28, 2025 BUY Buy
-3.8% avg upside
12 analysts
$16.00
36.35% Downside
 +54.7%
ADUS
Addus Homecare
 Jun 09, 2025 BUY Strong Buy
+21.8% avg upside
18 analysts
$133.00
26.53% Upside
 -20.5%
ENSG
The Ensign Group
 Feb 04, 2025 BUY Strong Buy
-3.8% avg upside
9 analysts
$166.00
1.37% Downside
 +19.3%
MD
Pediatrix Medical Group
 Jan 31, 2025 BUY Buy
-21.7% avg upside
14 analysts
$18.00
32.83% Downside
 +52.9%
BKD
Brookdale Senior Living
 Dec 19, 2024 BUY Strong Buy
-4.8% avg upside
11 analysts
$8.00
49.66% Downside
 +115.8%
ASTH
Astrana Health
 Dec 16, 2024 HOLD Strong Buy
+11.2% avg upside
16 analysts
$41.00
16.56% Downside
 -39.4%
AGL
Agilon Health
 Dec 16, 2024 HOLD Buy
-58.5% avg upside
26 analysts
$3.00
97.32% Downside
 -69.5%
PRVA
Privia Health Group
 Dec 16, 2024 BUY Strong Buy
+15.8% avg upside
26 analysts
$25.00
8.59% Downside
 +8.9%
SGRY
Surgery Partners
 Nov 19, 2024 BUY Strong Buy
+42.2% avg upside
18 analysts
 — -30.9%
NHI
National Health Investors
 Oct 25, 2023 HOLD Buy
-3.5% avg upside
17 analysts
$54.00
30.33% Downside
 +58.3%
LTC
LTC Properties
 Oct 25, 2023 BUY Hold
-10.9% avg upside
16 analysts
$36.00
8.32% Downside
 +21.6%
OHI
Omega Healthcare
 Jul 31, 2023 BUY Buy
-13.1% avg upside
29 analysts
$35.00
29.13% Downside
 +21.8%
CTRE
CareTrust REIT
 Jul 27, 2023 BUY Strong Buy
-12.8% avg upside
22 analysts
$23.00
44.84% Downside
 +33.4%
SBRA
Sabra Healthcare REIT
 Jul 27, 2023 HOLD Buy
-4.6% avg upside
28 analysts
$13.00
35.46% Downside
 +39.9%
PNTG
Pennant Group
 Feb 27, 2023 BUY Strong Buy
-8.1% avg upside
9 analysts
$16.00
58.55% Downside
 +11.5%
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Tao Qiu — Frequently Asked Questions
How accurate are Tao Qiu's stock ratings?
Based on the calls 13Foresight could measure, about 69% of Tao's ratings were profitable over a one-year hold, with an average return of +14.9% per rating, or -6.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Tao ranked on 13Foresight?
Tao Qiu is currently ranked #1167 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Tao cover?
Tao most recently has ratings on HCSG, ADUS, ENSG, MD, BKD, ASTH, AGL, PRVA, SGRY, NHI, LTC, OHI and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.